SCHEMBL17000063

SCHEMBL17000063

CNC(=O)c1cc(Oc2ccc(CNC(=O)Nc3cc(C(F)(F)F)c(C)cc3OCCNS(C)(=O)=O)cc2)ccn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDR2 Q16832 4/20 0.54
GSK3B P49841 2/20 0.53
RAF1 P04049 12/20 0.47
KDR P35968 5/20 0.46
RET P07949 4/20 0.46
BRAF P15056 3/20 0.46
EPHX2 P34913 3/20 0.46
AURKB Q96GD4 3/20 0.46
ABL1 P00519 3/20 0.46
EPHA2 P29317 3/20 0.46
MAPK14 Q16539 3/20 0.46
MAP3K20 Q9NYL2 3/20 0.46
SRC P12931 3/20 0.46
RIPK2 O43353 2/20 0.46
ABCB11 O95342 2/20 0.46
HTR1A P08908 2/20 0.46
PDGFRB P09619 2/20 0.46
ADORA3 P0DMS8 2/20 0.46
KIT P10721 2/20 0.46
FGFR1 P11362 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15574212 0.92 GSK3B (0.64) DDR2GSK3BRAF1KDRRET
SCHEMBL17000061 0.92 DDR2 (0.54) DDR2GSK3BRAF1KDRRET
SCHEMBL17000058 0.90 GSK3B (0.59) DDR2GSK3BRAF1KDRRET
SCHEMBL15574215 0.88 DDR2 (0.67) DDR2GSK3BRAF1KDRRET
SCHEMBL15574608 0.88 DDR2 (0.56) DDR2GSK3BRAF1KDRRET
SCHEMBL17000012 0.87 DDR2 (0.62) DDR2GSK3BRAF1KDRRET
SCHEMBL17000057 0.84 DDR2 (0.57) DDR2GSK3BRAF1KDRRET
SCHEMBL170909 0.84 GSK3B (0.68) DDR2GSK3BRAF1KDRRET
SCHEMBL17000059 0.83 DDR2 (0.53) DDR2GSK3BRAF1KDRRET
SCHEMBL15575221 0.83 GSK3B (0.66) DDR2GSK3BRAF1KDRRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS DDR2, DDR1, DDRGK1 DDR2 1/4885GSK3B 494/4885RAF1 3072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.